Excipients Used for Modified Nasal Drug Delivery: A Mini-Review of the Recent Advances
Abstract
:1. Introduction
2. Anatomy and Physiology of the Nose
3. Nasal Drug Delivery
4. Factors That Affect the Nasal Drug Absorption
5. Excipients Used in Modified Drug Release Semi-Solid Pharmaceutical Dosage Forms for Nasal Administration
5.1. Poloxamers
Nasal Dosage Form | Drug Release Rate * | API | Excipients | Refs. |
---|---|---|---|---|
in situ gel | biphasic | huperzine A | poloxamers (407, 188), CS, castor oil, polyoxyl 40 hydrogenated castor oil, 1,2- propanediol, Ringer’s solution | [37] |
in situ gel | biphasic | almotriptan | poloxamer (407, 188), Na-CMC, glyceryl behenate glyceryl palmitostearate, glyceryl monostearate, precirol | [38] |
in situ gel | biphasic | sumatriptan | poloxamers (407, 188), carrageenan, soybean phospholipids, cholesterol, tween 80, sodium caprate, sodium cholate, clostridium perfringens enterotoxin, sodium caprate | [39] |
in situ gel | controlled | ziprasidone | poloxamers (407, 188) β-cyclodextrin, HPMC E5, PEG 6000, PEG 4000, polyethylene, HPMCK4M | [40] |
in situ gel | controlled | geniposide | poloxamers (407, 188), HPMC, borneol, benzalkonium chloride, NaCl | [41] |
in situ gel | sustained | rivastigmine hydrogen tartrate | poloxamer 407, poly (lactic-co-glycolic acid), polymeric NPs | [42] |
in situ gel | sustained | mometasone furoate | poloxamer 407, Carbopol® 974P NF, PEG 400, NaCl, benzalkonium chloride, dexpanthenol, triethanolamine | [43] |
in situ gel | controlled | montelukast sodium | poloxamer 407, HPMC K4M, PEG 400, methyl paraben | [44] |
in situ gel | controlled | hydrocortisone | poloxamer 188, Carbopol 934, PG, benzalkonium chloride, triethanolamine, isopropyl alcohol | [45] |
NP | biphasic | pramipexole dihydrochloride | CS, sodium tripolyphosphate | [46] |
NP | biphasic | efavirenz | CS chloral hydrate, glucosamine chloral hydrate, N-acetylglucosamine, HP-β-CD, Tween 80 | [47] |
NP | controlled | sitagliptin | CS, glacial acetic acid, tripolyphosphate | [48] |
NP | delayed | human serum albumin | CS low molecular weight, acetic acid, mucin, sialic acid | [49] |
in situ misemgel | controlled | raloxifene hydrochloride | peppermint oil, n-propanolol, n-butanol, Tween® 80, PEG 200, PG, GG, TPGS, linoleic acid, Kolliphor®, RH 40 | [50] |
in situ gel loaded NPs | biphasic | voriconazole | GG, clove oil, nanotransferosomes, Tween 80, lecithin | [51] |
nanoemulsion | biphasic | quetiapine | Capmul MCM, Emalex LWIS 10, PEG 400, Transcutol P, Tween 80, water, Labrafil M 1944 CC, isopropyl myristate, sesame oil, Lauroglycol 90, miglyol 840 | [52] |
NPs | sustained | dolutegravir sodium | HP-β-CD, DPC, Tween 80, DMSO | [53] |
NPs | slow | acetylcholinesterase reactivator | L-α-phosphatidylcholine, 75% soybean phosphatidylcholine, dihexadecylmethylhydroxyethylammonium bromide, Tween 80, Phospholipon 80, Lipoid S75, 1-(o-tolylazo)-2-naphthol, pyrene, pyridine-2-aldoxime methochloride (Pralidoxime) | [54] |
5.2. Chitosan
5.3. Gellan Gum
5.4. Nanosized Drug Carriers
6. Excipients Used in Modified Drug Release Vaccines for Nasal Administration
6.1. Chitosan
Vaccine | Release Rate * | API | Excipients | Refs. |
---|---|---|---|---|
NPs | extended | Encephalitis-chimeric virus | trimethyl CS, glycol CS, 6-maleimidohexanoic acid, 1-ethyl-3-(3-dimethylamino propyl)carbodiimide, N-hydroxysuccinimide, sodium tripolyphosphate, phenylmethylsulphonyl fluoride, fluorescein isothiocyanate-conjugated bovine serum albumin, bovine serum albumin, polystyrene microplates, IFN-γ, IL-4 cytokine | [60] |
NPs | slow | plasmid DNA encoding 5p36/LACK leishmanial antigen | CS microparticles, glyceraldehyde | [61] |
NPs | controlled | bovine serum albumin | aminated CS, aminated and thiolated CS, CS, N-(2-hydroxyethyl) ethylenediamine, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, thioglycolic acid, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), trypsin-EDTA | [62] |
hydrogel | prolonged | antigen that generates nasal tissue resident memory CD8+ T cells | CS, poloxamers (188 and 407), ovalbumin protein, lipopolysaccharide | [65] |
NPs | biphasic | r4M2e.HSP70c antigen | N,N,N-trimethyl CS, trimethyl CS, glycerin | [66] |
NPs | biphasic | tetanus toxoid | CS, NPs, paraffin oil, nanospheres | [67] |
NPs | biphasic | tetanus toxoid | N-trimethyl CS, CS, dextran microspheres, tripolyphosphate, lactose, Span 80, Tween 80 | [68] |
NP | gradual | bovine serum albumin, ovalbumin, and myoglobin | low molecular weight CS, Compound 48/80, MTT (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), albumin-fluorescein isothiocyanate conjugate (FITC-BSA), trehalose, Dulbecco’s modified Eagle medium (DMEM) and Roswell Park Memorial Institute (RPMI), Bicinchoninic acid (BCA) assay and micro BCA kits, Fetal bovine serum (FBS), wheat germ agglutinin Alexa Fluor® 350 Conjugate and Lysotracker® Red DND 99 | [69] |
NPs | extended | PPE17 antigen (for tuberculosis) | CS, SA | [70] |
NP | burst release prevented | PR8 influenza virus | SA, CS, N,N,N-trimethyl CS, concanavalin A | [71] |
NPs | biphasic | inactivated influenza virus | SA powder, class B CpG ODN 2007 with a phosphorothioated backbone, 2,3-bis-(2-methoxy-4-nitro-5- sulfophenyl)-2H -tetra- zolium-5-carboxanilide, Tween 80 and Span 80 | [72] |
NPs | prolonged | bovine serum albumin | Poly(D,L-lactide-co-glycolide), Bisphenol-A-ethoxylate di-acrylate, ethylenediamine, tetrahydrofuran, poly(vinyl alcohol) | [73] |
nanogel | gradually | surface protein A fusion antigens | pullulan with 1.3% cholesterol and 23% amino residues | [74] |
nanogels | complete release in 6 h | Ovalbumin | squalane oil, cyclohexane, surfactant sucrose laurate (L-195) | [75] |
nanodispersion | prolonged | Ovalbumin | Epsiliseen®-H (ϵ-polylysine), dextran sulfate sodium salt, hydrogen chloride, sodium hydroxide | [76] |
6.2. Sodium Alginate
6.3. Nanosized Drug Carriers
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Sadeghi, S.; Lee, W.K.; Kong, S.N.; Shetty, A.; Drum, C.L. Oral administration of protein nanoparticles: An emerging route to disease treatment. Pharmacol. Res. 2020, 158, 104685. [Google Scholar] [CrossRef]
- Anselmo, A.C.; Gokarn, Y.; Mitragotri, S. Non-invasive delivery strategies for biologics. Nat. Rev. Drug Discov. 2018, 18, 19–40. [Google Scholar] [CrossRef] [PubMed]
- Dubey, S.K.; Parab, S.; Dabholkar, N.; Agrawal, M.; Singhvi, G.; Alexander, A.; Bapat, R.A.; Kesharwani, P. Oral peptide delivery: Challenges and the way ahead. Drug Discov. Today 2021, 26, 931–950. [Google Scholar] [CrossRef] [PubMed]
- Leonard, A.K.; Sileno, A.P.; Brandt, G.C.; Foerder, C.A.; Quay, S.C.; Costantino, H.R. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int. J. Pharm. 2007, 335, 138–146. [Google Scholar] [CrossRef] [PubMed]
- Rapoport, A.; Winner, P. Nasal delivery of antimigraine drugs: Clinical rationale and evidence base. Headache 2006, 46, 192–201. [Google Scholar] [CrossRef]
- Laffleur, F.; Bauer, B. Progress in nasal drug delivery systems. Int. J. Pharm. 2021, 607, 120994. [Google Scholar] [CrossRef]
- Illum, L. Nasal drug delivery—Recent developments and future prospects. J. Control. Release 2012, 161, 254–263. [Google Scholar] [CrossRef]
- Deli, M.A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta Biomembr. 2009, 1788, 892–910. [Google Scholar] [CrossRef]
- Wolburg, H.; Wolburg-Buchholz, K.; Sam, H.; Horvát, S.; Deli, M.A.; Mack, A.F. Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat. Histochem. Cell Biol. 2008, 130, 127–140. [Google Scholar] [CrossRef]
- Illum, L. Nasal drug delivery—Possibilities, problems and solutions. J. Control. Release 2003, 87, 187–198. [Google Scholar] [CrossRef]
- Pires, A.; Fortuna, A.; Alves, G.; Falcão, A. Intranasal drug delivery: How, why and what for? J. Pharm. Pharm. Sci. 2009, 12, 288–311. [Google Scholar] [CrossRef] [PubMed]
- Xi, J.; Si, X.A.; Kim, J.; Zhang, Y.; Jacob, R.E.; Kabilan, S.; Corley, R.A. Anatomical Details of the Rabbit Nasal Passages and Their Implications in Breathing, Air Conditioning, and Olfaction. Anat. Rec. 2016, 299, 853–868. [Google Scholar] [CrossRef] [PubMed]
- Gizurarson, S. The effect of cilia and the mucociliary clearance on successful drug delivery. Biol. Pharm. Bull. 2015, 38, 497–506. [Google Scholar] [CrossRef] [PubMed]
- Ugwoke, M.I.; Verbeke, N.; Kinget, R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2010, 53, 3–21. [Google Scholar] [CrossRef] [PubMed]
- Lazovic, G.D.; Daniel, R.K.; Janosevic, L.B.; Kosanovic, R.M.; Colic, M.M.; Kosins, A.M. Rhinoplasty: The nasal bones-anatomy and analysis. Aesthetic Surg. J. 2015, 35, 255–263. [Google Scholar] [CrossRef]
- Kim, D.; Kim, Y.H.; Kwon, S. Enhanced nasal drug delivery efficiency by increasing mechanical loading using hypergravity. Sci. Rep. 2018, 8, 1–9. [Google Scholar] [CrossRef]
- Bitter, C.; Suter-Zimmermann, K.; Surber, C. Nasal drug delivery in humans. Curr. Probl. Dermatol. 2011, 40, 20–35. [Google Scholar] [CrossRef]
- Mujawar, N.; Ghatage, S.; Navale, S.; Sankpal, B.; Patil, S.; Patil, S. Nasal Drug Delivery: Problem Solution and Its Application. J. Curr. Pharma Res. 2014, 4, 1231–1245. [Google Scholar] [CrossRef]
- Gosau, M.; Rink, D.; Driemel, O.; Draenert, F.G. Maxillary sinus anatomy: A cadaveric study with clinical implications. Anat. Rec. 2009, 292, 352–354. [Google Scholar] [CrossRef]
- Inoue, D.; Tanaka, A.; Kimura, S.; Kiriyama, A.; Katsumi, H.; Yamamoto, A.; Ogawara, K.I.; Kimura, T.; Higaki, K.; Yutani, R.; et al. The relationship between in vivo nasal drug clearance and in vitro nasal mucociliary clearance: Application to the prediction of nasal drug absorption. Eur. J. Pharm. Sci. 2018, 117, 21–26. [Google Scholar] [CrossRef]
- Tomazic, P.V.; Darnhofer, B.; Birner-Gruenberger, R. Nasal mucus proteome and its involvement in allergic rhinitis. Expert Rev. Proteom. 2020, 17, 191–199. [Google Scholar] [CrossRef] [PubMed]
- Evans, C.M.; Koo, J.S. Airway mucus: The good, the bad, the sticky. Pharmacol. Ther. 2009, 121, 332–348. [Google Scholar] [CrossRef] [PubMed]
- Roger, D.F. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir. Care 2007, 52, 1134–1146. [Google Scholar]
- Charlton, S.; Jones, N.S.; Davis, S.S.; Illum, L. Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device. Eur. J. Pharm. Sci. 2007, 30, 295–302. [Google Scholar] [CrossRef]
- Ali, A.; Wahlgren, M.; Rembratt-Svensson, B.; Daftani, A.; Falkman, P.; Wollmer, P.; Engblom, J. Dehydration affects drug transport over nasal mucosa. Drug Deliv. 2019, 26, 831–840. [Google Scholar] [CrossRef]
- Illum, L. Nasal drug delivery: New developments and strategies. Drug Discov. Today 2002, 7, 1184–1189. [Google Scholar] [CrossRef]
- Costa, C.; Moreira, J.N.; Amaral, M.H.; Sousa Lobo, J.M.; Silva, A.C. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J. Control. Release 2019, 295, 187–200. [Google Scholar] [CrossRef] [PubMed]
- Costantino, H.R.; Illum, L.; Brandt, G.; Johnson, P.H.; Quay, S.C. Intranasal delivery: Physicochemical and therapeutic aspects. Int. J. Pharm. 2007, 337, 1–24. [Google Scholar] [CrossRef]
- Tanaka, A.; Furubayashi, T.; Enomura, Y.; Hori, T.; Shimomura, R.; Maeda, C.; Kimura, S.; Inoue, D.; Kusamori, K.; Katsumi, H.; et al. Nasal drug absorption from powder formulations: Effect of fluid volume changes on the mucosal surface. Biol. Pharm. Bull. 2017, 40, 212–219. [Google Scholar] [CrossRef]
- Keller, L.A.; Merkel, O.; Popp, A. Intranasal drug delivery: Opportunities and toxicologic challenges during drug development. Drug Deliv. Transl. Res. 2022, 12, 735–757. [Google Scholar] [CrossRef]
- Varsha, B.; Abhijeet, K.; Kusum, R.; Gouri, D. An overview study on nasal and intranasal delivery system of drug. J. Med. Pharm. Allied Sci. 2020, 9, 2455–2465. [Google Scholar] [CrossRef]
- Wadell, C. Nasal drug delivery—In Vitro Studies on Factors Influencing Permeability and Implications on Absorption. Ph.D. Dissertation, Acta Universitatis Upsaliensis, Uppsala, Sweden, 2002. [Google Scholar]
- Ugwoke, M.I.; Agu, R.U.; Verbeke, N.; Kinget, R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 2005, 57, 1640–1665. [Google Scholar] [CrossRef]
- Russo, E.; Villa, C. Poloxamer hydrogels for biomedical applications. Pharmaceutics 2019, 11, 671. [Google Scholar] [CrossRef] [PubMed]
- Zarrintaj, P.; Ramsey, J.D.; Samadi, A.; Atoufi, Z.; Yazdi, M.K.; Ganjali, M.R.; Amirabad, L.M.; Zangene, E.; Farokhi, M.; Formela, K.; et al. Poloxamer: A versatile tri-block copolymer for biomedical applications. Acta Biomater. 2020, 110, 37–67. [Google Scholar] [CrossRef] [PubMed]
- Dumortier, G.; Grossiord, J.L.; Agnely, F.; Chaumeil, J.C. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 2006, 23, 2709–2728. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Cheng, G.; Hu, R.; Chen, S.; Lu, W.; Gao, S.; Xia, H.; Wang, B.; Sun, C.; Nie, X.; et al. A Nasal Temperature and pH Dual-Responsive In Situ Gel Delivery System Based on Microemulsion of Huperzine A: Formulation, Evaluation, and In Vivo Pharmacokinetic Study. AAPS PharmSciTech 2019, 20, 1–12. [Google Scholar] [CrossRef] [PubMed]
- Youssef, N.A.H.A.; Kassem, A.A.; Farid, R.M.; Ismail, F.A.; EL-Massik, M.A.E.; Boraie, N.A. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. Int. J. Pharm. 2018, 548, 609–624. [Google Scholar] [CrossRef]
- Omar, M.M.; Eleraky, N.E.; El Sisi, A.M.; Ali Hasan, O. Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. Drug Des. Dev. Ther. 2019, 13, 4413–4430. [Google Scholar] [CrossRef]
- Londhe, V.; Krishnan, S. Formulation, Evaluation, and Pharmacodynamic Investigation of Ziprasidone-b-cyclodextrin In-Situ Nasal Gel. Proceedings 2020, 78, 42. [Google Scholar] [CrossRef]
- Wang, Y.; Jiang, S.; Wang, H.; Bie, H. A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases. PLoS ONE 2017, 12, e0189478. [Google Scholar] [CrossRef]
- Salatin, S.; Barar, J.; Barzegar-Jalali, M.; Adibkia, K.; Jelvehgari, M. Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies. Colloids Surf. B Biointerfaces 2017, 159, 629–638. [Google Scholar] [CrossRef] [PubMed]
- Altuntaş, E.; Yener, G. Formulation and Evaluation of Thermoreversible In Situ Nasal Gels Containing Mometasone Furoate for Allergic Rhinitis. AAPS PharmSciTech 2017, 18, 2673–2682. [Google Scholar] [CrossRef] [PubMed]
- Durgapal, S.; Rana, M.; Mukhopadhyay, S.; Rana, A.J.; Goswami, L.; Joshi, S. Formulation and Evaluation of in-Situ Nasal Gel of Montelukast Sodium for the Effective Treatment of Asthma. Int. J. Pharm. Sci. Res. 2018, 9, 2792. [Google Scholar] [CrossRef]
- Khandagale, P.M.; Rokade, M.M.; Phadtare, D.G. Formulation Development and Evaluation of Nasal In- Situ Gel of Hydrocortisone. Asian J. Pharm. Technol. 2018, 8, 92–102. [Google Scholar] [CrossRef]
- Raj, R.; Wairkar, S.; Sridhar, V.; Gaud, R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int. J. Biol. Macromol. 2018, 109, 27–35. [Google Scholar] [CrossRef] [PubMed]
- Belgamwar, A.; Khan, S.; Yeole, P. Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting. Artif. Cells Nanomed. Biotechnol. 2018, 46, 374–386. [Google Scholar] [CrossRef] [PubMed]
- Wilson, B.; Mohamed Alobaid, B.N.; Geetha, K.M.; Jenita, J.L. Chitosan nanoparticles to enhance nasal absorption and brain targeting of sitagliptin to treat Alzheimer’s disease. J. Drug Deliv. Sci. Technol. 2021, 61, 102176. [Google Scholar] [CrossRef]
- Piazzini, V.; Landucci, E.; D’Ambrosio, M.; Tiozzo Fasiolo, L.; Cinci, L.; Colombo, G.; Pellegrini-Giampietro, D.E.; Bilia, A.R.; Luceri, C.; Bergonzi, M.C. Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery. Int. J. Biol. Macromol. 2019, 129, 267–280. [Google Scholar] [CrossRef]
- Ahmed, O.A.A.; Badr-Eldin, S.M. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: Formulation, characterization, and in vivo performance. Int. J. Nanomed. 2018, 13, 6325–6335. [Google Scholar] [CrossRef]
- Kammoun, A.K.; Khedr, A.; Hegazy, M.A.; Almalki, A.J.; Hosny, K.M.; Abualsunun, W.A.; Murshid, S.S.A.; Bakhaidar, R.B. Formulation, optimization, and nephrotoxicity evaluation of an antifungal in situ nasal gel loaded with voriconazole–clove oil transferosomal nanoparticles. Drug Deliv. 2021, 28, 2229–2240. [Google Scholar] [CrossRef]
- Boche, M.; Pokharkar, V. Quetiapine Nanoemulsion for Intranasal Drug Delivery: Evaluation of Brain-Targeting Efficiency. AAPS PharmSciTech 2017, 18, 686–696. [Google Scholar] [CrossRef] [PubMed]
- Belgamwar, A.V.; Khan, S.A.; Yeole, P.G. Intranasal dolutegravir sodium loaded nanoparticles of hydroxypropyl-beta-cyclodextrin for brain delivery in Neuro-AIDS. J. Drug Deliv. Sci. Technol. 2019, 52, 1008–1020. [Google Scholar] [CrossRef]
- Pashirova, T.N.; Zueva, I.V.; Petrov, K.A.; Lukashenko, S.S.; Nizameev, I.R.; Kulik, N.V.; Voloshina, A.D.; Almasy, L.; Kadirov, M.K.; Masson, P.; et al. Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model. Colloids Surf. B Biointerfaces 2018, 171, 358–367. [Google Scholar] [CrossRef] [PubMed]
- Javia, A.; Kore, G.; Misra, A. Chapter 11: Polymers in Nasal Drug Delivery: An Overview. In Applications of Polymers in Drug Delivery; Elsevier: Amsterdam, The Netherlands, 2021; ISBN 9780128196595. Available online: https://www.sciencedirect.com/science/article/pii/B9780128196595000112?via%3Dihub (accessed on 18 September 2022). [CrossRef]
- Shim, S.; Yoo, H.S. The Application of Mucoadhesive Chitosan Nanoparticles in Nasal Drug Delivery. Mar. Drugs 2020, 18, 605. [Google Scholar] [CrossRef]
- Pippa, N.; Forys, A.; Katifelis, H.; Chrysostomou, V.; Trzebicka, B.; Gazouli, M.; Demetzos, C.; Pispas, S. Design and development of DSPC:DAP:PDMAEMA-b-PLMA nanostructures: From the adumbration of their morphological characteristics to in vitro evaluation. Colloids Surf. A Physicochem. Eng. Asp. 2022, 632, 127768. [Google Scholar] [CrossRef]
- Pippa, N.; Lagopati, N.; Forys, A.; Chountoulesi, M.; Katifelis, H.; Chrysostomou, V.; Trzebicka, B.; Gazouli, M.; Demetzos, C.; Pispas, S. Aqueous Heat Method for the Preparation of Hybrid Lipid–Polymer Structures: From Preformulation Studies to Protein Delivery. Biomedicines 2022, 10, 1228. [Google Scholar] [CrossRef]
- Tai, J.; Han, M.; Lee, D.; Park, I.-H.; Lee, S.H.; Kim, T.H. Different Methods and Formulations of Drugs and Vaccines for Nasal Administration. Pharmaceutics 2022, 14, 1073. [Google Scholar] [CrossRef]
- Dumkliang, E.; Pamornpathomkul, B.; Patrojanasophon, P.; Ngawhirunpat, T.; Rojanarata, T.; Yoksan, S.; Opanasopit, P. Feasibility of chitosan-based nanoparticles approach for intranasal immunisation of live attenuated Japanese encephalitis vaccine. Int. J. Biol. Macromol. 2021, 183, 1096–1105. [Google Scholar] [CrossRef]
- Oliveira Gomes, D.C.; Lilian da Silva Costa Souza, B.; Schwedersky, R.P.; Covre, L.P.; Leonel de Matos Guedes, H.; Lopes, U.G.; Inês Ré, M.; Rossi-Bergmann, B. Intranasal immunization with chitosan microparticles enhances lack-dna vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis. Microbes Infect. 2021, 24, 104884. [Google Scholar] [CrossRef]
- Sinani, G.; Sessevmez, M.; Gök, M.K.; Özgümüş, S.; Alpar, H.O.; Cevher, E. Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination. Int. J. Pharm. 2019, 569, 118592. [Google Scholar] [CrossRef]
- Hanafy, N.A.N.; El-Kemary, M.A. Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment. Int. J. Biol. Macromol. 2022, 198, 101–110. [Google Scholar] [CrossRef]
- Xin, Y.; Song, G.; Cereda, M.; Kadlecek, S.; Hamedani, H.; Jiang, Y.; Rajaei, J.; Clapp, J.; Profka, H.; Meeder, N.; et al. Semiautomatic segmentation of longitudinal computed tomography images in a rat model of lung injury by surfactant depletion. J. Appl. Physiol. 2015, 118, 377–385. [Google Scholar] [CrossRef] [PubMed]
- Bedford, J.G.; Caminschi, I.; Wakim, L.M. Intranasal delivery of a chitosan-hydrogel vaccine generates nasal tissue resident memory CD8+ T cells that are protective against influenza virus infection. Vaccines 2020, 8, 572. [Google Scholar] [CrossRef] [PubMed]
- Dabaghian, M.; Latifi, A.M.; Tebianian, M.; NajmiNejad, H.; Ebrahimi, S.M. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model. Vaccine 2018, 36, 2886–2895. [Google Scholar] [CrossRef] [PubMed]
- Pirouzmand, H.; Khameneh, B.; Tafaghodi, M. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid. Pharm. Biol. 2017, 55, 212–217. [Google Scholar] [CrossRef] [PubMed]
- Kabiri, M.; Bolourian, H.; Dehghan, S.; Tafaghodi, M. The dry powder formulation of mixed cross-linked dextran microspheres and tetanus toxoid-loaded trimethyl chitosan nanospheres as a potent adjuvant for nasal delivery system. Iran. J. Basic Med. Sci. 2020, 24, 116–122. [Google Scholar] [CrossRef]
- Bento, D.; Jesus, S.; Lebre, F.; Gonçalves, T.; Borges, O. Chitosan plus compound 48/80: Formulation and preliminary evaluation as a hepatitis B vaccine adjuvant. Pharmaceutics 2019, 11, 72. [Google Scholar] [CrossRef]
- Najafi, A.; Ghazvini, K.; Sankian, M.; Gholami, L.; Amini, Y.; Zare, S.; Khademi, F.; Tafaghodi, M. T helper type 1 biased immune responses by PPE17 loaded core-shell alginate-chitosan nanoparticles after subcutaneous and intranasal administration. Life Sci. 2021, 282, 119806. [Google Scholar] [CrossRef]
- Mosafer, J.; Sabbaghi, A.H.; Badiee, A.; Dehghan, S.; Tafaghodi, M. Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization. Asian J. Pharm. Sci. 2019, 14, 216–221. [Google Scholar] [CrossRef]
- Dehghan, S.; Kheiri, M.T.; Abnous, K.; Eskandari, M.; Tafaghodi, M. Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits. Microb. Pathog. 2018, 115, 74–85. [Google Scholar] [CrossRef]
- Sinani, G.; Sessevmez, M.; Koray Gök, M.; Özgümüş, S.; Okyar, A.; Oya Alpar, H.; Cevher, E. Nasal vaccination with poly(β-amino ester)-poly(D,L-lactide-co-glycolide) hybrid nanoparticles. Int. J. Pharm. 2017, 529, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Yuki, Y.; Uchida, Y.; Sawada, S.I.; Nakahashi-Ouchida, R.; Sugiura, K.; Mori, H.; Yamanoue, T.; Machita, T.; Honma, A.; Kurokawa, S.; et al. Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery System. Mol. Pharm. 2021, 18, 1582–1592. [Google Scholar] [CrossRef] [PubMed]
- Kong, Q.; Kitaoka, M.; Tahara, Y.; Wakabayashi, R.; Kamiya, N.; Goto, M. Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses. Int. J. Pharm. 2019, 572, 118777. [Google Scholar] [CrossRef] [PubMed]
- Bonaccorso, A.; Carbone, C.; Tomasello, B.; Italiani, P.; Musumeci, T.; Puglisi, G.; Pignatello, R. Optimization of dextran sulfate/poly-L-lysine based nanogels polyelectrolyte complex for intranasal ovalbumin delivery. J. Drug Deliv. Sci. Technol. 2021, 65, 102678. [Google Scholar] [CrossRef]
Route (Absorption Site) | Advantages | Disadvantages | Barrier Properties and Delivery Challenges |
---|---|---|---|
Intravenous |
|
| None |
Subcutaneous |
|
|
|
Inhalation (lungs) |
|
|
|
Oral (intestines) |
|
|
|
Transdermal (skin) |
|
|
|
Nasal (nasal mucosa surface) |
|
|
|
Buccal (oral mucosal surface) |
|
|
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Protopapa, C.; Siamidi, A.; Pavlou, P.; Vlachou, M. Excipients Used for Modified Nasal Drug Delivery: A Mini-Review of the Recent Advances. Materials 2022, 15, 6547. https://doi.org/10.3390/ma15196547
Protopapa C, Siamidi A, Pavlou P, Vlachou M. Excipients Used for Modified Nasal Drug Delivery: A Mini-Review of the Recent Advances. Materials. 2022; 15(19):6547. https://doi.org/10.3390/ma15196547
Chicago/Turabian StyleProtopapa, Chrystalla, Angeliki Siamidi, Panagoula Pavlou, and Marilena Vlachou. 2022. "Excipients Used for Modified Nasal Drug Delivery: A Mini-Review of the Recent Advances" Materials 15, no. 19: 6547. https://doi.org/10.3390/ma15196547